Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MA-7107
- Development stage
- Preclinical
- Lead developer
- Maipl Therapeutics
- Modality
- Small Molecules
01
Overview
MA-7107 is a small molecule antagonist of the prostaglandin F2α (FP) receptor, currently under development by Maipl Therapeutics for the treatment of liver cancer. Licensed from Ferring Pharmaceuticals, the drug is designed to selectively inhibit PGF2α signaling, which is implicated in tumor progression and resistance. By targeting the FP receptor specifically, MA-7107 aims to augment the efficacy of chemotherapy, radiation, or immunotherapies while potentially offering a superior safety profile compared to traditional NSAIDs or COX-2 inhibitors, as it has minimal impact on other essential prostaglandin functions. It is currently in the IND-enabling stage of development.
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on MA-7107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MA-7107.